Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RiBVD for First Line Mantle Cell Lymphoma
NCT01457144Phase 2Completed
- Sponsor
- French Innovative Leukemia Organisation
- Start
- Oct 2011
- Primary completion
- Sep 2014
- Modality
- Monoclonal Antibodies, Modified Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, bendamustine, bortezomib in mantle cell lymphoma (MCL), sponsored by French Innovative Leukemia Organisation. Started Oct 2011; status: completed.
02
Drugs
rituximabbendamustinebortezomib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT01457144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01457144.